Magnetic and fluorescent Gd$_2$O$_3$:Yb$^{3+}$/Ln$^{3+}$ nanoparticles for simultaneous upconversion luminescence/MR dual modal imaging and NIR-induced photodynamic therapy

Jun Liu,¹,* Long Huang,²,3,* Xiumei Tian,₄ Xiaoming Chen,₄ Yuanzhi Shao,⁵ Fukang Xie,³ Dihu Chen,¹ Li Li²

¹School of Electronics and Information Technology and School of Physics, ²State Key Laboratory of Oncology in South China, Imaging Diagnosis and Interventional Center, ³Department of Histology and Embryology, Zhongshan School of Medicine, Sun Yat-Sen University, ⁴Department of Biomedical Engineering, Guangzhou Medical University, ⁵State Key Laboratory of Optronic Materials and Technologies, Sun Yat-Sen University, Guangzhou, People’s Republic of China

*These authors contributed equally to this work

Abstract: The development of upconversion nanoparticles (UCNs) for theranostics application is a new strategy toward the accurate diagnosis and efficient treatment of cancer. Here, magnetic and fluorescent lanthanide-doped gadolinium oxide (Gd$_2$O$_3$) UCNs with bright upconversion luminescence (UCL) and high longitudinal relaxivity ($r_2$) are used for simultaneous magnetic resonance imaging (MRI)/UCL dual-modal imaging and photodynamic therapy (PDT). In vitro and in vivo MRI studies show that these products can serve as good MRI contrast agents. The bright upconversion luminescence of the products allows their use as fluorescence nanoprobes for live cells imaging. We also utilized the luminescence-emission capability of the UCNs for the activation of a photosensitizer to achieve significant PDT results. To the best of our knowledge, this study is the first use of lanthanide-doped Gd$_2$O$_3$ UCNs in a theranostics application. This investigation provides a useful platform for the development of Gd$_2$O$_3$-based UCNs for clinical diagnosis, treatment, and imaging-guided therapy of cancer.

Keywords: upconversion nanoparticles, upconversion luminescence imaging, MR imaging, photodynamic therapy, singlet oxygen

Introduction

Cancer is still one of the most devastating human diseases, causing millions of deaths every year. Accurate diagnosis and efficient treatment of cancer are crucially important to increase the survival rate of patients. However, current diagnostic and therapeutic techniques are still far from satisfaction. Photodynamic therapy (PDT) is considered to be an effective technique for cancer treatment because it is cost-effective, highly localized, and has fewer side effects compared to radiation therapy and chemotherapy.¹⁻³ It involves local or systemic administration of a photosensitizer (PS), followed by irradiation of the target lesion with light of a specific wavelength. This triggers oxidative photodamage by the generation of reactive oxygen species, especially singlet oxygen, subsequently leading to tumor cell killing.⁴ However, most of the currently available PSs are activated by visible light (400–700 nm), which has a limited penetration depth in biological tissues. In contrast, the near-infrared (NIR) within the “optical transparency window” (700–1,100 nm) of biological tissues not only results in low photodamage by the generation of reactive oxygen species, especially singlet oxygen, subsequently leading to tumor cell killing.⁴ However, most of the currently available PSs are activated by visible light (400–700 nm), which has a limited penetration depth in biological tissues. In contrast, the near-infrared (NIR) within the “optical transparency window” (700–1,100 nm) of biological tissues not only results in low photodamage but also possesses high tissue penetration capability.⁵⁻⁷ A novel strategy of combining the PS with lanthanide-doped upconversion nanoparticles (UCNs) can overcome the previous limitations and has recently attracted interest in the field of malignant tumor...
therapy. In this novel system, UCNs activate the PS by visible light emission generated from sequential multiphoton NIR excitation via an anti-Stokes process.\textsuperscript{8-10}

In 2007, Zhang et al first reported the use of NaYF\textsubscript{3}:Yb\textsuperscript{3+}/Er\textsuperscript{3+} UCNs for PDT application.\textsuperscript{11} Since then, the UCNs have been used for PDT by many groups.\textsuperscript{12-14} Both the dopants and host of UCNs are important to achieve efficient PDT. There are two types of dopants ions in UCNs: a sensitizer to absorb the NIR light and an activator to emit photons and further activate the PS. The Yb\textsuperscript{3+} ion is the most commonly used sensitizer ion because its \(2F_{7/2} \rightarrow 2F_{5/2}\) transition has a large absorption cross-section around 980 nm. The Er\textsuperscript{3+} ion is a highly efficient activator because many of its f-f transitions resonant well with the \(2F_{7/2} \rightarrow 2F_{5/2}\) transition of Yb\textsuperscript{3+}. For effective PDT, the choice of the UCNs host is critical for obtaining good upconversion efficiency. A popular host material is NaYF\textsubscript{3}, which exhibits high upconversion efficiency due to the low phonon cutoff energy,\textsuperscript{15} thus attracting much interest in UCNs-based PDT and upconversion luminescence (UCL) imaging.\textsuperscript{16-19} Other fluorides containing Yb\textsuperscript{3+} (NaYbF\textsubscript{4}) and Gd\textsuperscript{3+} (NaGdF\textsubscript{4}) ions, which also function as computed tomography (CT) and magnetic resonance imaging (MRI) contrast agents,\textsuperscript{20-24} have been utilized to achieve simultaneous dual- or multimodal bioimaging with high sensitivity and high spatial resolution. These multifunctional nanoparticles can satisfy the high efficiency and accuracy requirements of clinical cancer theranostics.

Oxides, such as Gd\textsubscript{2}O\textsubscript{3}, ZrO\textsubscript{2}, and Y\textsubscript{2}O\textsubscript{3}, are also generally used as luminescence host materials owing to their desirable chemical durability, thermal stability, and lower phonon energy.\textsuperscript{25-27} Among these oxides, the Gd\textsubscript{2}O\textsubscript{3} nanoparticles also exhibit higher relaxivity than clinical Gd-DTPA, and have been considered as effective T\textsubscript{2} MR contrast agents.\textsuperscript{28-30} Thus, the lanthanide-doped Gd\textsubscript{2}O\textsubscript{3} nanoparticles have attracted attention in the dual-modal imaging. Zhou et al used the lanthanide-doped Gd\textsubscript{2}O\textsubscript{3} UCNs with the size of 10–270 nm as dual-modal nanoprobe for MR/UCL imaging.\textsuperscript{31} Liu et al reported the application of Gd\textsubscript{2}O\textsubscript{3}:Yb\textsuperscript{3+}/Er\textsuperscript{3+} nanorods (length of 90–150 nm and diameter of 10–25 nm) for CT/MRI/UCL multimodal imaging.\textsuperscript{32} Our recent work has focused on the synthesis and development of ultra-small (sub-10 nm) lanthanide-doped Gd\textsubscript{2}O\textsubscript{3} nanoparticles for MR/fluorescence dual-modal imaging.\textsuperscript{33-36} However, to the best of our knowledge, the ability of lanthanide-doped Gd\textsubscript{2}O\textsubscript{3} UCNs for theranostics application, which combines the diagnosis and treatment of cancer, has not previously been reported. In this contribution, the aim was to synthesis magnetic and fluorescent lanthanide-doped Gd\textsubscript{2}O\textsubscript{3} UCNs and simultaneously achieve MR/UCL dual-modal imaging and PDT. This study is part of a long term to improve the accuracy or possibilities to detect (or monitor) and treat cancer with MR/UCL dual-modal imaging and PDT by utilizing the magnetic and fluorescent properties of lanthanide-doped Gd\textsubscript{2}O\textsubscript{3} UCNs.

**Experimental section**

**Preparation and characterization of the UCNs**

The UCNs were prepared by a two-step method, as previously reported.\textsuperscript{37} Analytical grade powders of Gd\textsubscript{2}O\textsubscript{3}, Yb\textsubscript{2}O\textsubscript{3}, and Ln\textsubscript{n}O\textsubscript{3} (Ln = Tm, Ho, Er) in the stoichiometric ratio of 83:15:2 were used as the raw materials to fabricate targets via a solid-state reaction technique. The UCNs were prepared utilizing the laser ablation in liquid (LAL) technique, “top-down” strategy, which generates higher purity products efficiently, and has been applied to synthesizing a variety of nanomaterials.\textsuperscript{37} A schematic diagram of the formation mechanism of UCNs by LAL is shown in Scheme 1. The process starts with the penetration of laser pulse in the liquid and arrival to the Gd\textsubscript{2}O\textsubscript{3}:Yb\textsuperscript{3+}/Ln\textsuperscript{3+} target surface (Scheme 1B), then followed by a high-temperature and high-pressure plasma plume containing the ablated material produced at the target/liquid interface, accompanied by the emission of a shockwave (Scheme 1C). As there is continual absorption of laser pulse by the target, the plasma plume subsequent ultrasonic adiabatic expands into surrounding liquid (Scheme 1D).\textsuperscript{37} During the expansion, the plasma plume quickly cools down and releases energy to the deionized water, resulting in the nucleation of the Gd\textsubscript{2}O\textsubscript{3}:Yb\textsuperscript{3+}/Ln\textsuperscript{3+} UCNs and growth of nuclei (Scheme 1E). Meanwhile, the energy release of plasma plume to the liquid induces the generation of a cavitation bubble, which expands into the liquid.\textsuperscript{38} During its expansion, the temperature and pressure inside the bubble decreased rapidly and cause the collapse of the bubble. During the collapse, the pressure and temperature recover to the original values, and the high energy is released by emission of a second shockwave,\textsuperscript{38} finally the Gd\textsubscript{2}O\textsubscript{3}:Yb\textsuperscript{3+}/Ln\textsuperscript{3+} UCNs are formed and ejected into surrounding liquid (Scheme 1F). The ablated colloids were allowed to stand for 24 h, before the upper liquid was collected for further measurement.

The UC fluorescence spectrum of the collected upper liquid was measured at room temperature using an Edinburgh spectrofluorophotometer (FLS920, Edinburgh Instrument Ltd., Edinburgh, UK) equipped with a 980 nm NIR laser. The structure, morphology, and component of the products were characterized using an X-ray diffractometer (XRD, D-MAX2200 VPC, Tokyo, Japan), a transmission electron microscope (TEM, FEI Tecnai G2 Spirit, FEI Company,
Eindhoven, the Netherlands), and an X-ray photoelectron spectrometer (XPS, ESCALab 250, Thermo Fisher Scientific, Waltham, MA, USA), respectively.

**In vitro MRI measurements**

In vitro $T_1$-weighted MRI was performed by a 3.0T Siemens Trio MRI scanner (Siemens Medical Solutions, Erlangen, Germany). The TSE $T_1$ axial sequence was used with the following parameters: 5% dist. factor, FOV = 64 mm, slice thickness = 2.0 mm, TR = 600 ms, TE = 12 ms, no of averages = 6. In this study, various samples with Gd concentrations in the average 0–0.1 mM were measured. The signal intensities were analyzed using a picture archiving and communications system.

**In vivo MRI measurements**

BALB/c nude mice of 16±2 g weight were purchased from the Animal Experiment Centre of the Medical College, Sun Yat-Sen University (People’s Republic of China) and housed in a pathogen-free animal facility. The study protocol was approved by the Care and Use of Laboratory Animals of Sun Yat-sen University (Permit Numbers: SCXK (Guangdong)}
2011–0029). We strictly followed the Guide for the Care and Use of Laboratory Animals of Sun Yat-sen University during the study. The BALB/c nude mice were subcutaneously injected with 5×10⁶ nasopharyngeal carcinoma (NPC) CNE-2 cells in 100 μL phosphate-buffered saline (PBS). Ten days after tumor cell inoculation, mice with xenografted tumor of ~60 mm³ were anesthetized by intraperitoneal injection of 1% mebumalnatrium (10 μL/g), then injected with the Gd₃O₃:Yb³⁺/Er³⁺ UCNs (Gd³⁺, 15 μmol/kg) in 100 μL of PBS (1x buffer) via the tail vein, and scanned with the 3.0-T MRI system using a 3 inch in diameter surface coil constructed specifically for small animals. To prevent bias toward aberrantly enhanced regions, normalized histograms of signal intensity were generated for the entire tumor.

**Fluorescence imaging of cells**

Cells from a murine macrophage cells line (RAW 264.7 cells) were cultured under 5% CO₂ atmosphere at 37°C in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum, penicillin (100 units/mL), and streptomycin (100 mg/mL). The cells were incubated with the Gd₃O₃:Yb³⁺/Ln³⁺ UCNs (20 μg/mL) for 2 h. After co-incubation, the cells were washed with PBS to remove the remaining particles and dead cells and then observed under a laser scanning confocal microscope (LSM 710, Carl Zeiss, Jena, Germany), operating at an excitation wavelength of 980 nm.

**Cytotoxicity assay**

The human NPC cell lines (CNE2 cells, purchased from the Cell bank of Laboratory Animal Center, the Sun Yat-sen University Hospital, Guangzhou, People’s Republic of China, with the permit number SCYK [粤] 2016-0029) were incubated with UCNs concentrations of 20, 30, 40, and 50 μg/mL in 96-well plates for 4, 6, and 8 h and compared to culture media (DMEM) as the negative control and lipopolysaccharides as the positive control. After co-incubation, 20 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added for another 4 h of incubation. The culture medium was removed and 100 μL dimethyl sulfoxide added to dissolve the formazan crystals for 10 min. The absorbance at 490 nm was measured by a microplate reader (Bio-Rad, Hercules, CA, USA).

**Singlet oxygen assay**

Singlet oxygen is important in PDT as the singlet oxygen kills cancer cells. The photochemical method with 1,3-diphenylisobenzofuran (DPBF) is generally used to detect singlet oxygen.³⁹-⁴¹ The singlet oxygen decomposes DPBF, which has an absorption wavelength of ~410 nm, thus the decreases in DPBF absorbance indicate the generation of singlet oxygen. The UCNs (Gd₃O₃:Yb³⁺/Er³⁺, 3.5 μg/mL, 5 μL), PS (ZnPc, 0.75 μM, 5 μL), and DPBF (10 mM, 15 μL) in solvent were irradiated with NIR light (laser diode, wavelength 980 nm, continuous wave, 0.2 W/cm²). The DPBF absorbance was measured using a Scandrop spectrophotometer (Nanodrop 2000, Thermo Fisher Scientific, Waltham, MA, USA).

**In vitro PDT**

To understand the effects of PDT, the cell viability of CNE2 cells containing the UCNs and the PS was measured under NIR irradiation. The cancer cells (2×10⁴ cells/100 μL) were seeded into 96-well cell culture plates. Following cultivation under dark conditions in DMEM, the cells were treated with UCNs (Gd₃O₃:Yb³⁺/Er³⁺, 40 μg/mL) and the PS (ZnPc, 0.75, 1.5, and 3 μM), and compared to UCNs and ZnPc control groups. All groups were cultivated under the same conditions for 4 h. The cells were washed three times with PBS and replaced into fresh culture medium. The cells were then irradiated with NIR light (laser diode, wavelength 980 nm, continuous wave, 0.2 W/cm²). After the 30 min cultivation, the cell viability was measured by MTT assay.

**Results and discussion**

**Upconversion fluorescence properties of the Gd₃O₃:Yb³⁺/Ln³⁺ UCNs**

The sensitizer (Yb³⁺ ions) has a much larger absorption cross-section at 980 nm and a much higher concentration than the activator (Ln³⁺ ions), thus energy transfer upconversion is the main pathway in the combined Yb³⁺/Ln³⁺ system. Under NIR excitation at 980 nm, the Yb³⁺ ions continuously absorbed 980 nm photons and transfer the energy to the activator, resulting in photons emission. Figure 1A shows the upconversion fluorescence photograph of the collected UCNs colloids under excitation at 980 nm, as obtained by a digital camera without using any optical filters. The upconversion fluorescence colors obtained from the Yb³⁺/Tm³⁺, Yb³⁺/Ho³⁺, and Yb³⁺/Er³⁺ combinations are blue, green, and red, respectively, which are naked-eye compatible and reflect the entire spectrum. Figure 1B shows their corresponding fluorescence spectra in the range of 400–750 nm under excitation at 980 nm. The Gd₃O₃:Yb³⁺/Tm³⁺ UCNs exhibit three main upconversion emission bands in the visible spectrum, including a strong blue emission band at around 476 nm and two relatively weak red emission bands centered at 653 and 695 nm. The Gd₃O₃:Yb³⁺/Ho³⁺ UCNs have a strong green emission at 543 nm and a weak red emission at 667 nm, while the Gd₃O₃:Yb³⁺/Er³⁺ UCNs exhibit a strong red emission at around 672 nm and two quite weak green emissions at ~528 and 547 nm. Interestingly, the red emission of Gd₃O₃:Yb³⁺/Er³⁺ UCNs is enhanced remarkably.
Er\(^{3+}\) UCNs centered at 672 nm have a large red shift (over 10 nm) compared to the reported cubic counterpart.\(^{32,42}\)

Tm\(^{3+}\), Ho\(^{3+}\), and Er\(^{3+}\) ions are the most common activators in UCNs and possess their own ladder-like energy levels, as shown in Figure S1. The intense blue and weak red emissions of Gd\(_2\)O\(_3\);Yb\(^{3+}\)/Tm\(^{3+}\) UCNPs are assigned to the \(^1G_4 \rightarrow ^3H_{6}\) (476 nm), \(^3G_4 \rightarrow ^3H_{6}\) (653 nm), and \(^1F_3 \rightarrow ^3H_{6}\) (695 nm) transitions of Tm\(^{3+}\). For Gd\(_2\)O\(_3\);Yb\(^{3+}\)/Ho\(^{3+}\), the peak near 543 nm is assigned to the \(^3F_{4}/^5S_{2} \rightarrow ^3I_{6}\) transition of Ho\(^{3+}\), and a weak emission in red region comes from \(^5F_{3} \rightarrow ^3I_{4}\) (667 nm) transition. The intense red emission and two quite weak emissions in the green region of Gd\(_2\)O\(_3\);Yb\(^{3+}\)/Er\(^{3+}\) UCNPs are assigned to the \(^5F_{2} \rightarrow ^4I_{15/2}\) (672 nm), \(^4S_{2} \rightarrow ^4I_{15/2}\) (547 nm) and \(^2H_{11/2} \rightarrow ^2I_{15/2}\) (528 nm) transitions of Er\(^{3+}\), respectively. Thus, the different color fluorescence of the Gd\(_2\)O\(_3\);Yb\(^{3+}\)/Ln\(^{3+}\) nanoparticles indicates that the Yb\(^{3+}\), Tm\(^{3+}\), Ho\(^{3+}\), and Er\(^{3+}\) ions are successfully doped into the Gd\(_2\)O\(_3\) matrix.

### Structure, morphology, and component of Gd\(_2\)O\(_3\);Yb\(^{3+}\)/Ln\(^{3+}\); UCNs

The crystal structures of the Gd\(_2\)O\(_3\);Yb\(^{3+}\)/Ln\(^{3+}\) UCNs were characterized by XRD measurement. The collected UCNs colloids are dropped onto silicon substrates and evaporated for measurement. Figure 2 shows the XRD patterns of Gd\(_2\)O\(_3\);Yb\(^{3+}\)/Ln\(^{3+}\) UCNs. The peaks of the UCNs match well to standard monoclinic Gd\(_2\)O\(_3\) (PDF#42-1465). The strong narrow peaks are indicative of the high-quality crystallinity of the UCNs.

The typical TEM image, SAED pattern, HRTEM image, and size distribution histogram of the Gd\(_2\)O\(_3\);Yb\(^{3+}\)/Er\(^{3+}\) UCNs are shown in Figure 3A–D. The results show that the as-prepared UCNs possess a nearly spherical shape with a wide-sized distribution. The corresponding size distribution histogram of the nanoparticles, which is fitted by the Gauss function, shows an average diameter of ~7.8 nm. However, the size calculated from XRD data by Scherrer equation is ~17.43 nm. Figure 3C shows the high resolution TEM (HRTEM) of UCNs. Clearly, small and large particles coexist and possess high crystallinity. In general, small nanoparticles usually make the peaks of XRD become wider, and even no peak can be detected for the ultra-fine nanocrystals. We deduce that these high crystalline large nanoparticles may have much effect to enhance the signal of XRD measurement or large particles maybe picked in the XRD

---

**Figure 1** (A) Upconversion fluorescence images of the collected Gd\(_2\)O\(_3\);Yb\(^{3+}\)/Ln\(^{3+}\) UCNs colloids under excitation at 980 nm, obtained using a digital camera without the use of a filter. (B) Room temperature upconversion emission spectra of Gd\(_2\)O\(_3\);Yb\(^{3+}\)/Ln\(^{3+}\) UCNs under excitation at 980 nm.

**Abbreviation:** UCNs, upconversion nanoparticles.

**Figure 2** XRD patterns of the as-synthesized Gd\(_2\)O\(_3\);Yb\(^{3+}\)/Ln\(^{3+}\) UCNs compared to PDF#42-1465 for monoclinic Gd\(_2\)O\(_3\).

**Abbreviations:** UCNs, upconversion nanoparticles; XRD, X-ray diffractometer.
measurement. The presence of large rings in the selected area electron diffraction pattern (Figure 3B) is further evidence of a polycrystalline structure. The ring spacings matched well with the crystallographic planes of monoclinic Gd$_2$O$_3$ (PDF#42-1465). Taking the Gd$_2$O$_3$:Yb$^{3+}$/Er$^{3+}$ UCNs as an example, XPS was employed to confirm the components of the products. As shown in Figure S2, peaks at 1,220.4, 1,187.0, 184.0, and 169.5 eV denote Gd$_{3d}^{3/2}$, Gd$_{3d}^{5/2}$, Yb$_{4d}$, and Er$_{4d}$, respectively. The structure and component analyses demonstrate that Yb$^{3+}$/Er$^{3+}$ ions are successfully co-doped into the Gd$_2$O$_3$ host matrix.

**In vitro and in vivo MRI study**

Samples were fed into the tubes in various concentrations between 0 and 0.1 mM for measurement. Figure 4A shows the $T_1$-weighted MR images of the Gd$_2$O$_3$:Yb$^{3+}$/Ln$^{3+}$ UCNs and Gd-DTPA (clinical MRI contrast agent). The results reveal an enhanced brightness of the MRI signal with increasing UCNs concentration. For the same Gd concentration, the MRI using the UCNs as contrast agent is much brighter than those using Gd-DTPA, indicating that the Gd$_2$O$_3$:Yb$^{3+}$/Ln$^{3+}$ nanoparticles possess better contrast enhancement than Gd-DTPA. The longitudinal relaxivity ($r_1$) value was measured to understand its effectiveness from a quantitative perspective. As shown in Figure 4B, $R_1$ ($1/T_1$) vs Gd concentration curves were plotted, and the slopes of the curves or $r_1$ were obtained for each sample. The $r_1$ values of Gd$_2$O$_3$:Yb$^{3+}$/Tm$^{3+}$, Gd$_2$O$_3$:Yb$^{3+}$/Ho$^{3+}$, and Gd$_2$O$_3$:Yb$^{3+}$/Er$^{3+}$ UCNs are 13.23, 16.56, and 14.52 s$^{-1}$mM$^{-1}$, respectively. Note...
that the $r_1$ values of Gd$_2$O$_3$:Yb$^{3+}$/Ln$^{3+}$ UCNs are over three times higher than those of Gd-DTPA (4.16 s$^{-1}$mM$^{-1}$), which is consistent with the above contrast enhancement result.

Figure 4C illustrates the interaction between the contrast agents (Gd-DTPA and Gd$_2$O$_3$:Yb$^{3+}$/Ln$^{3+}$ UCNs) and water. The $r_1$ value of the contrast agent is proportional to the water hydration number which directly corresponds to the unpaired electrons of Gd$^{3+}$ ions. The Gd$^{3+}$ ions of Gd-DTPA can only offer one hydrate position since the other six unpaired electrons are coordinated by the chelates. However, a Gd$^{3+}$ ion on the surface of the UCNs can offer all its seven unpaired electrons for water hydration, resulting in a higher $r_1$ value than Gd-DTPA. The $T_1$-weighted MR images of the NPC CNE-2 xenografted tumor (white arrow) in BALB/c nude mice are shown in Figure 5. $T_1$-weighted images in the axial orientations were obtained at 0, 5, 10, 15, 30, 45, 60, and 90 min after intravenous administration of the Gd$_2$O$_3$:Yb$^{3+}$/Er$^{3+}$ nanoparticles and clearly show a high contrast enhancement of the tumor 30 min after injecting the Gd$_2$O$_3$:Yb$^{3+}$/Er$^{3+}$ nanoparticles. Therefore, both the in vitro and in vivo MR imaging investigations indicate that the Gd$_2$O$_3$:Yb$^{3+}$/Er$^{3+}$ nanoparticles may be a promising $T_1$-weighted MRI contrast agent for biomedical applications.

Confocal fluorescence imaging of live cells

The use of NIR light for the excitation of nanoparticles for molecular, cellular, and tissue imaging is very attractive in bioimaging applications owing to the lack of tissue damage and deep tissue penetrability. To explore the feasibility of using the UCNs as biological fluorescence probes, we conducted in vitro biological experiments using a murine macrophage cells line (RAW 264.7 cells) incubated with Gd$_2$O$_3$:Yb$^{3+}$/Ln$^{3+}$ UCNs. The cells were washed after incubation and imaged using a confocal laser fluorescence microscope operating at an excitation wavelength of 980 nm. As shown in Figures 6 and S3, blue, green, and red fluorescence can be observed from the cells incubated with the...
Figure 5 In vivo MRI of a NPC CNE-2 xenografted tumor after intravenous administration of the Gd$_2$O$_3$:Yb$^{3+}$/Er$^{3+}$ UCNs (Gd$^{3+}$, 15 μmol/kg) at 0, 5, 10, 15, 30, 45, 60, and 90 min, respectively.

Abbreviations: MRI, magnetic resonance imaging; NPC, nasopharyngeal carcinoma; UCNs, upconversion nanoparticles; min, minutes.

Figure 6 Confocal fluorescence images of RAW267.4 cells incubated with Gd$_2$O$_3$:Yb$^{3+}$/Ln$^{3+}$ UCNs under excitation at 980 nm.

Abbreviation: UCNs, upconversion nanoparticles.
Gd$_2$O$_3$:Yb$^{3+}$/Tm$^{3+}$, Gd$_2$O$_3$:Yb$^{3+}$/Ho$^{3+}$, and Gd$_2$O$_3$:Yb$^{3+}$/Er$^{3+}$ UCNs, respectively, with no autofluorescence found. The positions of the cells in the bright-field and the dark-field fluorescence imaging correlated well, and the fluorescence products were primarily located in the cell membrane and cytoplasm. The cells show good viability and morphology, suggesting that the products cause no significant damage to the cells. We also assessed the cells’ viability after incubation with Gd$_2$O$_3$:Yb$^{3+}$/Ln$^{3+}$ (Ln = Tm, Ho, and Er) UCNs (Figure S4). Clearly, there is no significant difference between the three kinds of nanoparticles and the negative control (PBS); the data showed that the cell toxicity of the three kinds of nanoparticles is satisfactory. This result indicates that the upconversion fluorescence emission of the UCNs is strong enough for live cell imaging and can be applied as potential fluorescence nanoprobes for in vivo imaging.

In vitro PDT

Cytotoxic singlet oxygen can result in cell death. Therefore, the ability to generate singlet oxygen is one of the crucial factors for effective PDT. Singlet oxygen production is generally monitored using DPBF, which reacts irreversibly with singlet oxygen causing a decrease of its characteristic absorption at ~410 nm.\textsuperscript{39–41} As shown in Figure 7A, the combination of the UCNs (Gd$_2$O$_3$:Yb$^{3+}$/Er$^{3+}$) with PS (ZnPc) resulted in the highest rate of decomposition of the DPBF under NIR irradiation, and thus absorption of DPBF decreased exponentially.

![Figure 7](https://www.dovepress.com/)

**Figure 7** (A) Peak absorbance intensity of DPBF as a function of NIR irradiation time. (B) Cell viability of CNE2 cells after incubation with UCNs concentrations of 20, 30, 40, and 50 μg/mL for 4, 6, and 8 h. (C) Schematic illustration of the UCNs-based PDT treatment. (D) PDT experiment (with UCNs and different PS concentrations) and control experiment.

**Abbreviations:** DMEM, Dulbecco’s Modified Eagle’s Medium; DPBF, 1,3-diphenylisobenzofuran; h, hours; LPS, lipopolysaccharides; min, minutes; NIR, near-infrared; PDT, photodynamic therapy; PS, photosensitizer; UCNs, upconversion nanoparticles.
with increasing NIR irradiation time, confirming the efficient generation of singlet oxygen.

To understand the effects of PDT, the viability of cells containing the combination of UCNs and PS under NIR irradiation was studied. First, the viability of CNE2 cells after incubation with UCNs concentrations of 20, 30, 40, and 50 μg/mL for 4, 6, and 8 h was determined by MTT assay. As shown in Figure 7B, the UCNs have no significant intrinsic toxicity effect on the cells’ survival. Then, the viability of CNE2 cells containing Gd-based UCNs (Gd3O2:Yb3+/Er3+, 40 μg/mL) and the ZnPc (0.75, 1.5, and 3 μM) under NIR irradiation was measured and compared to the control experiment. The UCNs-based PDT treatment is schematically illustrated in Figure 7C. The NIR irradiation of the UCNs emitted red light (~672 nm), excited the ZnPc (maximum absorption peak at ~670 nm), which then generated singlet oxygen to kill the cancer cells. The results shown in Figure 7D demonstrate that the cells’ viabilities of samples containing combinations of UCNs and ZnPc are lower than their control groups, meaning that this NIR-induced PDT can inhibit the proliferation of cancer cells.

**Conclusion**

In summary, magnetic and fluorescent lanthanide-doped Gd2O3 UCNs imaging have been fabricated and can simultaneously achieve MR/UCI dual-modal imaging and PDT. As an MRI contrast agent, the products show a high longitudinal relaxivity (r2) value and T1-weighted contrast enhancement of xenografted tumors in mice. As UCL imaging nanoprobes, the products exhibit bright luminescence under NIR irradiation. Moreover, upon NIR excitation, PDT can be achieved by the combination of the UCNs and the PS ZnPc. We anticipate that the magnetic and fluorescent lanthanide-doped Gd2O3 UCNs will be a highly attractive addition to the theranostic platform, and promote the development of “detect-to-treat” strategies or imaging-guided therapy of cancer.

**Acknowledgments**

This work was supported by the National Basic Research Program of China (2014CB931700), the National Natural Science Foundation of China (grant nos 81471787, 61471401, 81471711, 81271622, and 11274394), the National Science Foundation for Young Scholars of China (grant no 81401462), Natural Science Foundation of Guangdong, China (no 2014A030311036), and State Key Laboratory of Optoelectronic Materials and Technologies (Sun Yat-Sen University; no OEMT-2015-KF-03).

**Author contributions**

JL, LH, XT, XC, YS, and FX: experimental work. DC and LL: project planning. All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Lucky SS, Soo KC, Zhang Y. Nanoparticles in photodynamic therapy. *Chem Rev*. 2015;115(4):1990–2042.
2. Chen Z, Li Z, Wang J, et al. A multi-synergistic platform for sequential irradiation-activated high-performance apotic cancer therapy. *Adv Funct Mater*. 2013;23(4):522–529.
3. Bonnett R. Photosensitizers of the porphyrin and phthalocyanine series for photodynamic therapy. *Chem Soc Rev*. 1995;24(1):19–33.
4. Rosenkranz AA, Jans DA, Sobolev AS. Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency. *Immunol Cell Biol*. 2000;78(4):452–464.
5. Wei W, Zhang Y, Chen R, et al. Cross relaxation induced pure red upconversion in activator- and sensitizer-rich lanthanide nanoparticles. *Chem Mater*. 2014;26(18):5183–5186.
6. Chen GY, Shen J, Ohulchansky TY, et al. (α-NaYbF4,Tm3+)/CaF2 core/shell nanoparticles with efficient near-infrared to near-infrared upconversion for high-contrast deep tissue bioimaging. *ACS Nano*. 2012;6(9):8280–8287.
7. Li RB, Ji ZX, Dong JY, et al. Enhancing the imaging and biosafety of upconversion nanoparticles through phosphonate coating. *ACS Nano*. 2015;9(3):3293–3306.
8. Ayuzz F. Upconversion and anti-stokes processes with f and d ions in solids. *Chem Rev*. 2004;104(1):139–174.
9. Wang L, Yan R, Hoo Z, et al. Fluorescence resonant energy transfer biosensor based on upconversion-luminescent nanoparticles. *Angew Chem Int Ed Engl*. 2005;44(37):6054–6057.
10. Haase M, Schäfer H. Upconverting nanoparticles. *Angew Chem Int Ed Engl*. 2011;50(26):5808–5829.
11. Zhang P, Steelant W, Kumar M, Scholfield M. Versatile photosensitizers for photodynamic therapy at infrared excitation. *J Am Chem Soc*. 2007;129(15):4526–4527.
12. Idris NM, Gananasammandhan MK, Zhang J, Ho PC, Mahendran R, Zhang Y. In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers. *Nat Med*. 2012;18(10):1580–1585.
13. Chatterjee DK, Yong Z. Upconverting nanoparticles as nanotransducers for photodynamic therapy in cancer cells. *Nanomedicine*. 2008;3(1):73–82.
14. Wang M, Chen Z, Zheng W, et al. Lanthanide-doped upconversion nanoparticles electrostatically coupled with photosensitizers for near-infrared-triggered photodynamic therapy. *Nanoscale*. 2014;6(14):8274–8282.
15. Chen G, Qiu H, Prasad PN, Chen X. Upconversion nanoparticles: design, nanochemistry, and applications in theranostics. *Chem Rev*. 2014;114(10):5161–5214.
16. Cui S, Chen H, Zhu H, et al. Amphiphilic chitosan modified upconversion nanoparticles for in vivo photodynamic therapy induced by near-infrared light. *J Mater Chem*. 2012;22(11):4861–4873.
17. Guo HC, Qian HS, Idris NM, Zhang Y. Singlet oxygen-induced apoptosis of cancer cells using upconversion fluorescent nanoparticles as a carrier of photosensitizer. *Nanomedicine*. 2010;6(3):486–495.
18. Qian HS, Guo HC, Ho PC, Mahendran R, Zhang Y. Mesoporous-silica-coated up-conversion fluorescent nanoparticles for photodynamic therapy. *Small*. 2009;5(20):2285–2290.
19. Liu K, Liu X, Zeng Q, et al. Covalently assembled NIR nanoplatform for simultaneous fluorescence imaging and photodynamic therapy of cancer cells. *ACS Nano*. 2012;6(5):4054–4062.
20. Jin S, Zhou L, Gu Z, et al. A new near infrared photosensitizing nanoplatform containing blue-emitting up-conversion nanoparticles and hypoxorhodin A for photodynamic therapy of cancer cells. *Nanoscale*. 2013;5(23):11910–11918.
21. Park YI, Kim HM, Kim JH, et al. Theranostic probe based on lanthanide-doped nanoparticles for simultaneous in vivo dual-modal imaging and photodynamic therapy. *Adv Mater*. 2012;24(42):5755–5761.
22. Qiao XF, Zhou JC, Xiao JW, Wang YF, Sun LD, Yan CH. Tripl-functional core–shell structured upconversion luminescent nanoparticles covalently grafted with photosensitizer for luminescent, magnetic resonance imaging and photodynamic therapy in vitro. *Nanoscale*. 2012;4(15):4611–4623.
23. Zhao Z, Han Y, Lin C, et al. Multifunctional core–shell upconverting nanoparticles for imaging and photodynamic therapy of liver cancer cells. *Chem Asian J*. 2012;7(4):830–837.
24. Chen Q, Wang C, Cheng L, He W, Cheng Z, Liu Z. Protein modified upconversion nanoparticles for imaging-guided combined photothermal and photodynamic therapy. *Biomaterials*. 2014;35(9):2915–2923.
25. Zheng K, Zhang D, Zhao D, Liu N, Shi F, Qin W. Bright white upconversion emission from Yb³⁺, Er³⁺, and Tm³⁺-codoped Gd₂O₃ nanotubes. *Phys Chem Chem Phys*. 2010;12(27):7620–7625.
26. Chen GY, Zhang YG, Somesfalen G, Zhang ZG, Sun Q, Wang FP. Two-color upconversion in rare-earth-ion-doped ZrO₂ nanocrystals. *Appl Phys Lett*. 2006;89(16):163105.
27. Chen GY, Liu Y, Zhang YG, et al. Bright white upconversion luminescence in rare-earth-ion-doped Y₂O₃ nanocrystals. *Appl Phys Lett*. 2007;91(13):3103.
28. Park JY, Baek MJ, Choi ES, et al. Paramagnetic ultrasmall gadolinium oxide nanoparticles as advanced T₂ MRI contrast agent: account for large longitudinal relavixity, optimal particle diameter, and in vivo T₂ MR images. *ACS Nano*. 2009;3(11):3663–3669.
29. Klasson A, Ahren M, Hellqvist E, et al. Positive MRI contrast enhancement in THP-1 cells with Gd₃O₃ nanoparticles. *Contrast Media Mol Imaging*. 2008;3(3):106–111.
30. Ahren M, Selegard L, Klasson A, et al. Synthesis and characterization of PEGylated Gd₃O₃ nanoparticles for MRI contrast enhancement. *Langmuir*. 2010;26(8):5753–5762.
31. Zhou L, Gu Z, Liu X, et al. Size-tunable synthesis of lanthanide-doped Gd₂O₃ nanoparticles and their applications for optical and magnetic resonance imaging. *J Mater Chem*. 2012;22(3):966–974.
32. Liu Z, Pu F, Huang S, Yuan Q, Ren J, Qu X. Long-circulating Gd₂O₃:Yb³⁺, Er³⁺ up-conversion nanoprobe as high-performance contrast agents for multi-modality imaging. *Biomaterials*. 2013;34(6):1712–1721.
33. Chen F, Chen M, Yang C, et al. Terbium-doped gadolinium oxide nanoparticles prepared by laser ablation in liquid for use as a fluorescence and magnetic resonance imaging dual-modal contrast agent. *Phys Chem Chem Phys*. 2015;17(2):1189–1196.
34. Liu J, Tian XM, Luo NQ, et al. Sub-10 nm monoclinic Gd₂O₃:Eu³⁺ nanoparticles as dual-modal nanoprobes for magnetic resonance and fluorescence imaging. *Langmuir*. 2014;30(43):13005–13013.
35. Luo N, Yang C, Tian X, et al. A general top-down approach to synthesize rare earth doped-Gd₂O₃ nanocrystals as dual-modal contrast agents. *J Mater Chem B*. 2014;2(35):5891–5908.
36. Liu J, Deng H, Huang Z, Chen D, Shao Y. Phonon-assisted energy back transfer-induced multicolor upconversion emission of Gd₂O₃:Yb³⁺/Er³⁺ nanoparticles under near-infrared excitation. *Phys Chem Chem Phys*. 2015;17(23):15412–15418.
37. Yang GW. Laser ablation in liquids: applications in the synthesis of nanocrystals. *Prog Mater Sci*. 2007;52(4):648–698.
38. Yan Z, Chrisey DB. Pulsed laser ablation in liquid for micro-/nanostructure generation. *J Photochem Photobiol C: Photochem Rev*. 2012;13(3):204–223.
39. Fujii M, Usui M, Hayashi S, et al. Singlet oxygen formation by porous Si in solution. *Phys Status Solidi A*. 2005;202(8):1385–1389.
40. Mukai K, Ouchi A, Takahashi S, et al. Development of singlet oxygen absorption capacity (SOAC) assay method. 3. measurements of the SOAC values for phenolic antioxidants. *J Agric Food Chem*. 2012;60(32):7905–7916.
41. Ikehata T, Onodera Y, Nonokawa T, et al. Photodynamic therapy using upconversion nanoparticles prepared by laser ablation in liquid. *Appl Surf Sci*. 2015;348:54–59.
42. Lei Y, Song H, Yang L, et al. Upconversion luminescence, intensity saturation effect, and thermal effect in Gd₂O₃:Er³⁺, Yb³⁺ nanowires. *J Chem Phys*. 2005;123(17):174710.
43. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. *Chem Soc Rev*. 2006;35(6):512–523.
Supplementary materials

Figure S1 Schematic illustration of the UC emission process (A), and the proposed UC mechanism schemes (B, C) of the Gd₂O₃:Yb³⁺/Ln⁺ (Ln = Tm, Ho, and Er) UCNs. Abbreviations: NIR, near-infrared; UC, upconversion; ET, energy transfer; Ex, excitation; Em, emission.
Figure S2 Gd3d, Yb4d, and Er4d XPS spectra of Gd$_2$O$_3$:Yb$^{3+}$/Er$^{3+}$ UCNs.
Figure S3 Confocal fluorescence images of Raw267.4 cells incubated with Gd₃O₃·Yb³⁺/Ln³⁺ UCNs.

Figure S4 Cells viability of Raw267.4 cells incubated with Gd₃O₃·Yb³⁺/Ln³⁺ (Ln = Tm, Ho, and Er) UCNs (20μg/mL at 2 hours.

Abbreviations: LPS, lipopolysaccharides; PBS, phosphate-buffered saline.

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.